A review of the venous thrombotic issues associated with multiple myeloma.

about

Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.

P2860

Q37144501-3B6897A4-FC80-4FF1-88B5-2221AB714E38

P2860

A review of the venous thrombotic issues associated with multiple myeloma.

Item

http://www.wikidata.org/entity/Q38845946

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A review of the venous thrombotic issues associated with multiple myeloma.

@en

type

Item

label

A review of the venous thrombotic issues associated with multiple myeloma.

@en

prefLabel

A review of the venous thrombotic issues associated with multiple myeloma.

@en

P1476

A review of the venous thrombotic issues associated with multiple myeloma.

@en

P2093

Despina Fotiou

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Grigoris Gerotziafas

http://www.w3.org/2001/XMLSchema#string

P2860

Microparticles as Biomarkers of Blood Coagulation in Cancer

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance

The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

P304

695-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2016.1194750

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2016-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27232265

http://www.w3.org/2001/XMLSchema#string

A review of the venous thrombotic issues associated with multiple myeloma.

about

P2860

P2860

A review of the venous thrombotic issues associated with multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698